Publicaciones en colaboración con investigadores/as de Columbia University Medical Center (6)

2023

  1. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

    European Journal of Cancer, Vol. 178, pp. 23-33

2022

  1. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  2. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    npj Breast Cancer, Vol. 8, Núm. 1

2021

  1. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156

  2. Sacituzumab govitecan in metastatic triple-negative breast cancer

    New England Journal of Medicine, Vol. 384, Núm. 16, pp. 1529-1541

2019

  1. Treatment outcomes of immune-related cutaneous adverse events

    Journal of Clinical Oncology, Vol. 37, Núm. 30, pp. 2746-2758